Jonathan Reiner, MD
Interventional Cardiology · Washington, DCNPI 1649349226
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $65,857 of the $77,048 with a category attached, or 85.5%. Merit Medical Systems Inc accounts for 85.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $69,209 and has fallen 97.4% since, to $1,827 in 2025.
Across 253 payments — averaging $304.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merit Medical Systems Inc$66K
- Edwards Lifesciences$4K
- Abbott$3K
- Medtronic$1K
- Cardiovascular Systems Inc.$953
- Boston Scientific$300
- plus $2K from 24 others
Across 38 payments — averaging $2162.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$46K
- Janssen Research & Development, LLC$37K
- Abiomed$147
What the payments were for
- Royalty or licence$65,85785%
- Travel & lodging$3,7495%
- Food & beverage$7,44110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merit Medical Systems Inc | 4 | $65,857 |
| Edwards Lifesciences | 61 | $4,050 |
| Abbott | 23 | $3,110 |
| Medtronic(2 entities) | 33 | $1,147 |
| Cardiovascular Systems Inc. | 60 | $953 |
| Boston Scientific | 13 | $300 |
| Abiomed | 4 | $223 |
| Terumo Medical Corporation | 3 | $210 |
| Cook Medical LLC | 8 | $143 |
| Amgen | 5 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $125 |
| Cvrx, Inc. | 1 | $101 |
| Angiodynamics, Inc. | 4 | $94 |
| Shockwave Medical, Inc | 3 | $69 |
| Teleflex LLC | 2 | $66 |
| W. L. Gore & Associates, Inc. | 3 | $54 |
| Kestra Medical Technology Services, Inc. | 1 | $49 |
| Recor Medical Inc | 2 | $46 |
| Atricure, Inc. | 1 | $45 |
| Inari Medical, Inc. | 1 | $42 |
| Stryker | 2 | $40 |
| Pfizer | 2 | $35 |
| Novo Nordisk | 1 | $34 |
| Novartis | 1 | $30 |
| CSL Behring | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MBA Hemostasis Valve$65,857
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,630
- Mitra Clip system$1,111
- TRICLIP$1,003
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$804
- SAPIEN 3 Ultra RESILIA$590
- MitraClip$376
- SYMPLICITY G3$323
- METACROSS OTW$182
- NAVITOR$160
- Impella$146
- ONYX FRONTIER$128
- Micra$101
- Barostim Neo System$101
How this compares
Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 48 | $55,354 |
| EliquisApixaban | 33 | $43,399 |
| Repatha SureclickEvolocumab | 39 | $34,118 |
| XareltoRivaroxaban | 19 | $24,604 |
| JardianceEmpagliflozin | 31 | $22,502 |
| Rosuvastatin Calcium | 97 | $2,643 |
| Ranolazine ErRanolazine | 21 | $2,133 |
| Ezetimibe | 96 | $2,055 |
| Metoprolol Succinate | 137 | $2,030 |
| Atorvastatin Calcium | 165 | $1,782 |
| Losartan Potassium | 40 | $609 |
| Nifedipine ErNifedipine | 31 | $605 |
| Amlodipine Besylate | 74 | $572 |
| ClopidogrelClopidogrel Bisulfate | 61 | $547 |
| Carvedilol | 36 | $383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $30 | $55,35448 claims |
| PfizerEliquis | $35 | $43,39933 claims |
| Johnson & JohnsonXarelto | $15 | $24,60419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Washington
- Ron WaksmanWashington$915K
- Toby RogersWashington$880K
- Augusto PichardWashington$180K
- Lowell SatlerWashington$112K
- Brian CaseWashington$63K
- Horst SievertWashington$58K
- Nelson BernardoWashington$55K
- Ramesh MazhariWashington$41K
- Itshac Ben-DorWashington$25K
- Nardos TemesgenWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.